Quality of life with durvalumab in stage III non-small-cell lung cancer
Mené sur 713 patients atteints d'un cancer du poumon non à petites cellules de stade III non résécable, cet essai de phase III évalue la toxicité, du point de vue des symptômes et de la qualité de vie déclarés par les patients, du durvalumab dispensé après une chimioradiothérapie (durée médiane de suivi : 25,2 mois)
In The Lancet Oncology, Rina Hui and colleagues report the patient-reported outcomes (PROs) data of the PACIFIC study. The PACIFIC study set a new standard of care in patients with stage III non-small-cell lung cancer, finding a significant benefit in survival with adjuvant durvalumab after chemoradiotherapy compared with placebo. Evaluation of health-related quality of life (HRQOL), showed that the addition of durvalumab was not detrimental to HRQOL; for example, physical functioning (mean change from baesline to week 12 0·1 [95% CI −1·10 to 1·28] in the durvalumab group vs 2·0 [0·22 to 3·73] in the placebo group) and global health status or quality of life (2·6 [1·21 to 3·94] vs 1·8 [–0·25 to 3·81]) remained stable with both treatments.
The Lancet Oncology 2019